Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

, REGN

Regeneron

$390.38

-7.78 (-1.95%)

07:13
11/29/16
11/29
07:13
11/29/16
07:13

Ophthotech has no read through from competitor failure, says SunTrust

After Regeneron's (REGN) REGN2176-3 for wet AMD failed to show significant efficacy in a Phase II trial, SunTrust analyst Yatin Suneja does not believe that the failure bodes badly for Ophthotech (OPHT) whose Fovista treatment, like Regeneron's (REGN) drug, utilizes the PDGF pathway. The analyst says that Ophthotech's Fovista "has shown impressive efficacy in both Phase I and Phase IIb studies," and Suneja expects Fovista's Phase III results to also show strong efficacy. The analyst reiterates a $100 price target and a Buy rating on Ophthotech.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

REGN

Regeneron

$390.38

-7.78 (-1.95%)

  • 03

    Dec

  • 29

    Mar

OPHT Ophthotech
$34.54

-4.42 (-11.35%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $23
GSCO
Sell
Ophthotech price target lowered to $23 from $45 at Goldman
Goldman analyst Terence Flynn lowered Ophthotech's (OPHT) price target to $23 from $45 and reiterated his Sell rating. He revised is thesis on Ophthotech following Regeneron's (REGN) recent negative Phase II data for its co-formulation of Eylea with Rinucumab and is incrementally more cautious on success for Fovista currently in Phase III trials.
REGN Regeneron
$390.38

-7.78 (-1.95%)

11/07/16
CHDN
11/07/16
NO CHANGE
CHDN
Regeneron shyness on drug prices negative, says Chardan
Chardan analyst Gbola Amusa says that Regeneron's reluctance to comment on drug pricing pressures during its Q3 earnings call is very unusual for a large drug company. The analyst says that this development creates risk that "pricing dynamics for Regeneron are either unknown...or are perhaps so negative that consensus estimates would be downwardly revised if a robust discussion were to have occurred." The analyst believes that, for Regeneron's Eylea treatment to meet consensus estimates, data on three upcoming, competing products will have to be negative, and all pricing pressure on drugs would have to disappear. He keeps a Sell rating on the stock.
11/07/16
LEER
11/07/16
NO CHANGE
Target $504
LEER
Outperform
Regeneron price target lowered to $504 from $513 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron (REGN) to $504 from $513 on valuation. Porges expects near-term volatility for the stock given questions regarding the upcoming second interim analysis of the Odyssey Outcomes trial for Praluent, the restart of trials for pain treatment fasinumab after the FDA's clinical hold, and the issues regarding development partner Sanofi's (SNY) fill-finish plant leading to sarilumab's Complete Response Letter last week. He reiterates an Outperform on Regeneron's shares.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

CATY

Cathay General

$36.99

0.08 (0.22%)

16:42
06/26/17
06/26
16:42
06/26/17
16:42
Syndicate
Breaking Syndicate news story on Cathay General »

Cathay General files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMCF

Emclaire Financial

16:39
06/26/17
06/26
16:39
06/26/17
16:39
Hot Stocks
Emclaire Financial appoints Engles as CFO, Lucco as risk and strategy chief »

Emclaire Financial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

, ECA

Encana

$8.42

-0.04 (-0.47%)

16:36
06/26/17
06/26
16:36
06/26/17
16:36
Hot Stocks
TIER REIT acquires Texas office tower, sells remaining Louisville portfolio »

TIER REIT (TIER)…

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

ECA

Encana

$8.42

-0.04 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

AL

Air Lease

$36.84

0.28 (0.77%)

, BA

Boeing

$199.98

-2.25 (-1.11%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Air Lease announces delivery of Boeing 737-800 to Royal Air Maroc »

Air Lease (AL) announced…

AL

Air Lease

$36.84

0.28 (0.77%)

BA

Boeing

$199.98

-2.25 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

PANL

Pangaea Logistics

$2.69

-0.1 (-3.58%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Breaking Hot Stocks news story on Pangaea Logistics »

VR Advisory Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XL

XL Group

$43.62

0.21 (0.48%)

16:33
06/26/17
06/26
16:33
06/26/17
16:33
Hot Stocks
XL-Cayman waives financing condition for tender offers »

XL Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$17.08

1.28 (8.10%)

16:32
06/26/17
06/26
16:32
06/26/17
16:32
Hot Stocks
Breaking Hot Stocks news story on Valeant »

Paulson & Co. reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

TOPS

TOP Ships

$0.68

-0.12 (-15.00%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
TOP Ships reports $4.2M in cash, cash equivalents post reverse stock split »

TOP Ships reports its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTI

PCTEL

$6.95

-0.21 (-2.93%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
PCTEL raises quarterly dividend 10% to 5.5c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

16:30
06/26/17
06/26
16:30
06/26/17
16:30
Options
Preliminary option volume of 13.3M today »

Preliminary option volume…

FNJN

Finjan Holdings

$3.62

-0.18 (-4.74%)

16:29
06/26/17
06/26
16:29
06/26/17
16:29
Syndicate
Finjan Holdings announces common stock offering, no amount given »

Finjan Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
06/26/17
06/26
16:20
06/26/17
16:20
Options
Closing CBOE SPX and VIX Index summary for June 26th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$88.17

3.34 (3.94%)

, LRLCY

L'Oreal

$43.61

1.53 (3.64%)

16:18
06/26/17
06/26
16:18
06/26/17
16:18
General news
On The Fly: Top stock stories for Monday »

The major averages began…

NSRGY

Nestle

$88.17

3.34 (3.94%)

LRLCY

L'Oreal

$43.61

1.53 (3.64%)

STOR

Store Capital

$23.11

2.34 (11.27%)

BRK.A

Berkshire Hathaway

$251,480.00

-320 (-0.13%)

BRK.B

Berkshire Hathaway

$167.47

0.25 (0.15%)

CAR

Avis Budget

$27.67

3.43 (14.15%)

GOOG

Alphabet

$952.27

-13.32 (-1.38%)

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

HTZ

Hertz

$10.83

1.29 (13.52%)

AAPL

Apple

$145.82

-0.46 (-0.31%)

SGEN

Seattle Genetics

$56.55

-5.19 (-8.41%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.77

-0.11 (-0.43%)

SSYS

Stratasys

$24.39

-3.22 (-11.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

$NSD

NASDAQ Market Internals

16:17
06/26/17
06/26
16:17
06/26/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWM

New Media

$13.62

0.27 (2.02%)

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Hot Stocks
New Media rebrands propel business services unit, renames it UpCurve »

New Media Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALG

Alamo Group

$91.52

1.1925 (1.32%)

16:15
06/26/17
06/26
16:15
06/26/17
16:15
Hot Stocks
Alamo Group completes acquisition of Old Dominion Brush Company »

Alamo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$111.10

-0.9 (-0.80%)

16:13
06/26/17
06/26
16:13
06/26/17
16:13
Syndicate
bluebird bio announces offering of $350M of common stock »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$53.74

-0.59 (-1.09%)

16:12
06/26/17
06/26
16:12
06/26/17
16:12
Periodicals
PayPal's Venmo tests debit card, Recode says »

PayPal's Venmo has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

KMPH

KemPharm

$3.40

0.05 (1.49%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
KemPharm granted patent for KP746, a prodrug of oxymorphone »

KemPharm announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Conference/Events
Federal Reserve Bank President of San Francisco speaks on global growth »

San Francisco Federal…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

, HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
Steel Partners, Handy & Harman sign definitive merger agreement »

Steel Partners Holdings…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$42.87

-1.47 (-3.32%)

16:10
06/26/17
06/26
16:10
06/26/17
16:10
Hot Stocks
Esperion says FDA confirms pathway for approval of bempedoic, ezetimib combo »

Esperion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$92.66

-0.68 (-0.73%)

16:09
06/26/17
06/26
16:09
06/26/17
16:09
Earnings
Breaking Earnings news story on Western Digital »

Western Digital backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$92.66

-0.68 (-0.73%)

16:08
06/26/17
06/26
16:08
06/26/17
16:08
Earnings
Western Digital raises Q4 adjusted EPS view to $2.85 from $2.55-$2.65 »

Consensus $2.65. Backs Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.